Bio-Techne Corp is a biotechnology company that specializes in developing and producing high-quality biotechnology tools and reagents for the life sciences market. The company offers a wide range of products, including proteins, antibodies, assays, and diagnostic tools, which are used by researchers and clinical laboratories for various applications, such as drug development, diagnostics, and disease research. With a focus on innovation, Bio-Techne aims to provide cutting-edge solutions that enhance research capabilities and improve patient outcomes in healthcare. Read More
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Washington D.C. – September 30, 2025 – Shares of Agilent Technologies (NYSE: A) experienced a significant upward movement today, closing strong amidst breaking news of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE). This surge, echoing similar positive movements for other life sciences companies like
As of September 30, 2025, the financial markets are grappling with the implications of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE), a move signaling a broader governmental push to significantly lower prescription drug costs. While such developments typically send ripples across the entire
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
jumped 5.3% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
The financial markets are abuzz following the Federal Reserve's recent decision to cut interest rates, a move widely interpreted as an attempt to inject new vigor into the economy. This policy shift immediately reduces the cost of borrowing for corporations, a critical factor influencing decisions on new investments and hiring.
The Federal Reserve has announced a 0.25% reduction in its benchmark interest rate, marking a significant shift towards a more accommodative monetary policy. This move, while seemingly modest, carries profound implications for the financial markets, signalling the central bank's intent to provide economic stimulus amidst evolving global and domestic
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
fell 4.8% in the afternoon session after the company presented a cautious outlook at the Baird Global Healthcare Conference, highlighting significant market challenges despite some areas of growth.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and alignment with sector valuations.
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
fell 3.3% in the afternoon session after the major indices continued to retreat (Nasdaq -1.5%, S&P 500 -1.2%) amid profit-taking and renewed concerns about tariffs. The decline was not driven by company-specific news but rather widespread negative sentiment as investors returned from the Labor Day holiday. Major U.S. indexes, including the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, all tumbled. The downturn was fueled by a mix of factors, including rising Treasury yields and fresh uncertainty after a court decision ruled most of President Trump's tariffs illegal. Although the tariffs remain in place pending appeal, the news contributed to market turbulence on the first trading day of what is historically the stock market's most challenging month.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospect of lower borrowing costs bolstered investor confidence, particularly in sectors that have lagged, leading to a broad rally across the market.
Investor sentiment is overwhelmingly pointing towards a significant shift in the Federal Reserve's monetary policy, with a near-certainty of a 25-basis-point interest rate cut anticipated at its September meeting. This widespread expectation, currently hovering around a 92% probability, is sending ripples through financial markets, influencing everything from stock valuations to
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
